JP2010505104A - 膵管腺癌に関連する新規の抗原及び抗体 - Google Patents

膵管腺癌に関連する新規の抗原及び抗体 Download PDF

Info

Publication number
JP2010505104A
JP2010505104A JP2009529713A JP2009529713A JP2010505104A JP 2010505104 A JP2010505104 A JP 2010505104A JP 2009529713 A JP2009529713 A JP 2009529713A JP 2009529713 A JP2009529713 A JP 2009529713A JP 2010505104 A JP2010505104 A JP 2010505104A
Authority
JP
Japan
Prior art keywords
pda
enolase
antibodies
protein
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009529713A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010505104A5 (enExample
Inventor
ノベッリ，フランチェスコ
トマイノ，バルバラ
カペッロ，パオラ
Original Assignee
リボバックス バイオテクノロジーズ ソシエテ アノニム
ビオリネ ディアニョスティーチ ソチエタ レスポンサビリタ リミテ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by リボバックス バイオテクノロジーズ ソシエテ アノニム, ビオリネ ディアニョスティーチ ソチエタ レスポンサビリタ リミテ filed Critical リボバックス バイオテクノロジーズ ソシエテ アノニム
Publication of JP2010505104A publication Critical patent/JP2010505104A/ja
Publication of JP2010505104A5 publication Critical patent/JP2010505104A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • G01N33/57525—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/01—Hydro-lyases (4.2.1)
    • C12Y402/01011—Phosphopyruvate hydratase (4.2.1.11), i.e. enolase
    • G01N33/575—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/988—Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2009529713A 2006-09-29 2007-09-28 膵管腺癌に関連する新規の抗原及び抗体 Pending JP2010505104A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06121552 2006-09-29
EP06126726 2006-12-20
PCT/EP2007/060305 WO2008037792A1 (en) 2006-09-29 2007-09-28 Novel antigens and antibodies associated to pancreatic ductal adenocarcinoma

Publications (2)

Publication Number Publication Date
JP2010505104A true JP2010505104A (ja) 2010-02-18
JP2010505104A5 JP2010505104A5 (enExample) 2010-10-07

Family

ID=38895810

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009529713A Pending JP2010505104A (ja) 2006-09-29 2007-09-28 膵管腺癌に関連する新規の抗原及び抗体

Country Status (18)

Country Link
US (1) US8071721B2 (enExample)
EP (1) EP2069395B1 (enExample)
JP (1) JP2010505104A (enExample)
KR (1) KR20090094227A (enExample)
CN (1) CN101578295B (enExample)
AT (1) ATE542831T1 (enExample)
AU (1) AU2007301966B2 (enExample)
BR (1) BRPI0717282A2 (enExample)
CA (1) CA2664841A1 (enExample)
DK (1) DK2069395T3 (enExample)
EA (1) EA016731B1 (enExample)
ES (1) ES2381304T3 (enExample)
IL (2) IL197868A (enExample)
NO (1) NO20091662L (enExample)
NZ (1) NZ576409A (enExample)
PL (1) PL2069395T3 (enExample)
PT (1) PT2069395E (enExample)
WO (1) WO2008037792A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012500964A (ja) * 2008-05-09 2012-01-12 デューク ユニバーシティ 癌の検出と治療における自己抗体
IT1398782B1 (it) 2009-09-11 2013-03-18 Novelli Peptide monofosforilato isolato derivato dall'alfa-enolasi umana utile per la diagnosi e il trattamento dell'adenocarcinoma pancreatico, anticorpi diretti contro il suddetto peptide monofosforilato e loro usi.
ITTO20120523A1 (it) * 2012-06-15 2013-12-16 Natimab Therapeutics S R L Procedimento e kit per la diagnosi in vitro dell'adenocarcinoma duttale pancreatico o per determinare la predisposizione all'adenocarcinoma duttale pancreatico
RU2656153C1 (ru) * 2013-12-20 2018-05-31 Девелопмент Сентер Фор Байотекнолоджи Антитела, специфичные к альфа-энолазе, и способы применения в противоопухолевой терапии
MX2016009102A (es) 2014-01-13 2016-09-09 Berg Llc Composiciones de enolasa 1 (eno1) y sus usos.
CN115786317A (zh) * 2022-12-12 2023-03-14 江苏三联生物工程股份有限公司 重组神经元特异性烯醇化酶及其制备方法与应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753446A (en) * 1993-04-15 1998-05-19 National Jewish Center For Immunology & Respiratory Medicine Mitogen ERK kinase kinase (MEKK) assay

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753446A (en) * 1993-04-15 1998-05-19 National Jewish Center For Immunology & Respiratory Medicine Mitogen ERK kinase kinase (MEKK) assay

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
JPN6012046513; Ｎａｔ．　Ｂｉｏｔｅｃｈｎｏｌ． Ｖｏｌ．２３，　Ｎｏ．１, 2005, ｐｐ．９４-１０１ *
JPN6012046516; Ｅｌｅｃｔｒｏｐｈｏｒｅｓｉｓ Ｖｏｌ．２１，　Ｎｏ．１３, 2000, ｐｐ．２６２２-２６３６ *
JPN6012046519; Ｍｏｌ．　Ｂｉｏｌ．　Ｃｅｌｌ Ｖｏｌ．１６，　Ｎｏ．１０, 2005, ｐｐ．４７６５-４７８０ *
JPN6012046520; Ｃａｎｃｅｒ　Ｒｅｓ． Ｖｏｌ．６４，　Ｎｏ．２４, 2004, ｐｐ．９０１８-９０２６ *
JPN6012046523; Ｊ．　Ｂｉｏｃｈｅｍ． Ｖｏｌ．１１７，　Ｎｏ．３, 1995, ｐｐ．５５４-５５９ *
JPN6012046525; Ｊ．　Ｉｍｍｕｎｏｌ． Ｖｏｌ．１７６，　Ｓｕｐｐｌｅｍｅｎｔ, 20060401, ｐ．Ｓ２６８ *

Also Published As

Publication number Publication date
WO2008037792A1 (en) 2008-04-03
PL2069395T3 (pl) 2012-06-29
IL197868A0 (en) 2011-08-01
IL197868A (en) 2013-03-24
CA2664841A1 (en) 2008-04-03
AU2007301966B2 (en) 2013-02-21
EA200970332A1 (ru) 2009-10-30
DK2069395T3 (da) 2012-05-14
EP2069395A1 (en) 2009-06-17
EP2069395B1 (en) 2012-01-25
PT2069395E (pt) 2012-04-27
NO20091662L (no) 2009-06-29
ES2381304T3 (es) 2012-05-25
IL218442A0 (en) 2012-04-30
KR20090094227A (ko) 2009-09-04
ATE542831T1 (de) 2012-02-15
CN101578295B (zh) 2013-02-27
BRPI0717282A2 (pt) 2013-10-15
US20100028907A1 (en) 2010-02-04
EA016731B1 (ru) 2012-07-30
US8071721B2 (en) 2011-12-06
CN101578295A (zh) 2009-11-11
AU2007301966A1 (en) 2008-04-03
NZ576409A (en) 2012-02-24

Similar Documents

Publication Publication Date Title
Leiphrakpam et al. Ezrin expression and cell survival regulation in colorectal cancer
AU2010311540A1 (en) PODXL protein in colorectal cancer
US8071721B2 (en) Antigens and antibodies associated to pancreatic ductal adenocarcinoma
He et al. Phosphatidylethanolamine binding protein 4 (PEBP4) is a secreted protein and has multiple functions
Martucciello et al. Anti-type 2 transglutaminase antibodies as modulators of type 2 transglutaminase functions: a possible pathological role in celiac disease
Sheng et al. SENP1-mediated deSUMOylation of YBX1 promotes colorectal cancer development through the SENP1-YBX1-AKT signaling axis
Milone et al. Proteomic analysis of zoledronic-acid resistant prostate cancer cells unveils novel pathways characterizing an invasive phenotype
Zhang et al. Generation and characterization of an anti-GP73 monoclonal antibody for immunoblotting and sandwich ELISA
EP3042203B1 (en) Biomarkers for cholangiocellular carcinoma (ccc)
Aggelis et al. Proteomic identification of differentially expressed plasma membrane proteins in renal cell carcinoma by stable isotope labelling of a von Hippel‐Lindau transfectant cell line model
Lončar-Brzak et al. Expression of small leucine-rich extracellular matrix proteoglycans biglycan and lumican reveals oral lichen planus malignant potential
WO2010071788A1 (en) Pancreatic cancer markers and uses thereof
CA2909474C (en) New method for monitoring cancer and/or inflammatory reaction based on relb phosphorylation
Álvarez-Fernández et al. Serological immune response against ADAM10 pro-domain is associated with favourable prognosis in stage III colorectal cancer patients
Thakar et al. SUMOylation of the hepatoma‐derived growth factor negatively influences its binding to chromatin
Ye et al. Direct molecular dissection of tumor parenchyma from tumor stroma in tumor xenograft using mass spectrometry-based glycoproteomics
Dziadosz-Brzezińska et al. Considerations for antibody-based detection of NRF2 in human cells
AU2006261856A1 (en) csPCNA isoform modifications and uses thereof
WO2013022841A1 (en) Nitrated sphingosine 1-phosphate 3 receptor as a predictor of acute lung injury-associated mortality
Akyildiz Demir et al. Identification of cytoplasmic sialidase NEU2-associated proteins by LC-MS/MS
Tian et al. USP13 Regulates the Breast Tumor Proliferation and Migration through the Stabilization of PDCD4 Protein
Semaan Proteomics of putative protein biomarkers in human breast cancer tissues
EP3346271A1 (en) Methods and kits for detecting cancer
JP2012515544A (ja) Ｐｔａ０８９タンパク質
WO2011140478A2 (en) Compositions and methods for detecting acetylated sumo proteins

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20100819

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100819

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120904

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121204

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121211

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130130

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20131015